Muhammad Zaman, "Access, Quality, and Pricing: Low and Middle Income Countries"
PLEASE NOTE: THESE SLIDES MAY NOT DISPLAY PROPERLY ONLINE, BUT THEY ARE READABLE IF DOWNLOADED. October 28, 2018 This one-day conference explored the current pharmaceutical pricing landscape by bringing together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assessed the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explored and articulated best practices to expand access to medicines and worked toward developing a plan for disseminating these practices more widely.
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Muhammad Zaman, "Access, Quality, and Pricing: Low and Middle Income Countries"
Similar to Muhammad Zaman, "Access, Quality, and Pricing: Low and Middle Income Countries" (20)
More from The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
More from The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics (20)
Recently uploaded
Recently uploaded (20)
Muhammad Zaman, "Access, Quality, and Pricing: Low and Middle Income Countries"
- 1. Access, Quality and Pricing: Innovation Challenges in Low and Middle Income Countries Muhammad H. Zaman Departments of Biomedical Engineering and International Health Howard Hughes Medical Institute Boston University June 14, 2018 1
- 4. Counterfeit and Substandard Medicines: A Global Challenge • Poor quality medicines make up 30 – 50% of drug sales worldwide • Causes > 250,000 preventable deaths annually • Poor quality medicines account for US$ 75 billion of US$ 962 billion global pharmaceutical market • Poor quality medicines contribute to drug- resistant infection and disease • Artemisinin resistant malaria on Thailand-Cambodia border 4
- 5. Existing Field Solutions GPHF MiniLab® Field Standard Spectrometers FDA CD3/4 • Chemical Analysis (TLC) • Inexpensive • Bulky (200 lbs) & labor intensive • Qualitative results • Chemical fingerprinting • Non-destructive • Semi-quantitative • High batch variability • Packaging Analysis • Non-destructive • Not analytical • Counterfeit-oriented 5
- 6. PharmaChk: The Device Accurately and affordably test the quality of medicines in the field through the quantification of active pharmaceutical ingredient and analysis of dissolution properties Current Prototype: Test antimalarials and antibitoics 6
- 7. PharmaChk • Portable platform • Optical quantification • Specific chemistry • No sample preparation 7Desai and Zaman, 2015 (Anal. Methods)
- 8. The Access-Quality-Pricing Nexus (Pakistan case study) • The foundations of Drug Regulatory Authority of Pakistan • Current focus on pricing and not access • Impact on discovery, innovation and manufacturing • The tension between quality and pricing 29 November 2018 8
- 9. Open Questions at Access-Quality-Pricing Nexus • Innovation and the future of local manufacturing • API versus finished product imports; biologics manufacture • The tension between quality and pricing: perception and reality • Quality as a metric of UHC • Innovation and the road to UHC 29 November 2018 9
Editor's Notes
- Rethink strategy new approaches;